(3-methylphenyl)methyl-triphenyl-λ5-phosphane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-methylphenyl)methyl-triphenyl-λ5-phosphane
• 化学式: C₂₆H₂₅P
• 分子量: 368.4
• InChiKey: OIRFBYVQCFHMDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• PYRIDONE COMPOUND
  申请人：Kamikubo Takashi

  公开号：US20100179137A1

  公开（公告）日：2010-07-15

  [Solving Means] The present inventors have conducted extensive studies on an EP4 receptor agonist, and as a result, found that a novel pyridone compound characterized in that the 1-position in the pyridone ring is substituted with a group having an acidic group such as a carboxyl group and the 6-position is bonded with an aromatic ring group via lower alkyl, lower alkylene, ether, or thioether, has an excellent EP4 receptor agonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor agonistic action and a blood flow increasing action in the hindlimb of a rat, it is useful as a pharmaceutical, in particular, an agent for treating peripheral arterial occlusive disease.

  【解决方法】本发明者对EP4受体激动剂进行了广泛的研究，并发现一种新型吡啶酮化合物，其特征在于吡啶酮环中的1位被取代为具有酸性基团（如羧基）的基团，而6位则通过较低的烷基、烷基烷基、醚或硫醚与芳香环基团结合，具有极好的EP4受体激动作用，从而完成了本发明。由于本发明的化合物在大鼠后肢具有出色的EP4受体激动作用和增加血流的作用，因此可用作制药用途，特别是治疗周围动脉闭塞性疾病的药物。
• PLANOGRAPHIC PRINTING PLATE MATERIAL, PLANOGRAPHIC PRINTING PLATE, PLANOGRAPHIC PRINTING PLATE PREPARING PROCESS AND PRINTING PROCESS EMPLOYING PLANOGRAPHIC PRINTING PLATE
  申请人：Sampei Takeshi

  公开号：US20090110832A1

  公开（公告）日：2009-04-30

  The present invention provides an intermediate transfer member having higher transferability and higher cleaning properties and durability, an apparatus for producing an intermediate transfer member which does not require the provision of any large equipment such as vacuum equipment, and an image forming apparatus comprising the intermediate transfer member. The intermediate transfer member contains a support and, provided on the support, a first inorganic compound layer containing carbon atoms and a second inorganic compound layer as a surface layer, the second inorganic compound layer not containing any carbon atom or containing carbon atoms in a smaller amount than the carbon atoms in the first inorganic compound layer.
• HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF
  申请人：UNIVERSITÉ DE MONTRÉAL

  公开号：US20210387980A1

  公开（公告）日：2021-12-16

  Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed. Such cancers include acute myeloid leukemia (AML), preferably AML characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (A/K), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.